Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

Ratios

vs
industry
vs
history
PE Ratio 19.86
PID's PE Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PID: 19.86 )
Ranked among companies with meaningful PE Ratio only.
PID' s PE Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 19.96
Current: 19.86
0
19.96
PE Ratio without NRI 19.86
PID's PE Ratio without NRI is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PID: 19.86 )
Ranked among companies with meaningful PE Ratio without NRI only.
PID' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0  Med: 0 Max: 19.96
Current: 19.86
0
19.96
PB Ratio 1.61
PID's PB Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PID: 1.61 )
Ranked among companies with meaningful PB Ratio only.
PID' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.64
Current: 1.61
0
1.64

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.73
PID's Dividend Yield % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PID: 3.73 )
Ranked among companies with meaningful Dividend Yield % only.
PID' s Dividend Yield % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 4.19
Current: 3.73
0
4.19
5-Year Yield-on-Cost % 3.72
PID's 5-Year Yield-on-Cost % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PID: 3.72 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PID' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 4.19
Current: 3.72
0
4.19

More Statistics

Short Percentage of Float0.00%
52-Week Range $13.21 - 15.08
Shares Outstanding (Mil)52,650,000.00
» More Articles for PID

Headlines

Articles On GuruFocus.com
Bill Ackman Comments on Zoetis Mar 30 2017 
Bill Ackman Comments on Canadian Pacific Railway Limited Mar 30 2017 
Bill Ackman Comments on Restaurant Brands International Mar 30 2017 
Bill Ackman Comments on Platform Specialty Products Mar 30 2017 
Bill Ackman Comments on Nomad Mar 30 2017 
Bill Ackman Comments on Mondelez Mar 30 2017 
Bill Ackman Comments on The Howard Hughes Corporation Mar 30 2017 
Bill Ackman Comments on Herbalife Mar 30 2017 
Bill Ackman Comments on Fannie Mae, Freddie Mac Mar 30 2017 
Bill Ackman Comments on Chipotle Mexican Grill Mar 30 2017 

More From Other Websites
Reduced Co-pays May Boost Demand for Entresto Mar 30 2017
Performance of GlaxoSmithKline’s Vaccines Business in 2016 Mar 30 2017
GlaxoSmithKline’s Pharmaceuticals Segment Performance Mar 29 2017
With low yields abroad, investors hunt for international dividend funds Mar 28 2017
Sandoz: Novartis’s Generics Business in 2016 Mar 27 2017
Novartis’s Innovative Medicines Segment in 2016 Mar 27 2017
What Happened to Sanofi’s Valuation after 4Q16? Feb 21 2017
This Keeps Driving Sanofi’s Growth Feb 20 2017
GlaxoSmithKline’s Consumer Healthcare Reports Growth in 4Q16 Feb 16 2017
GlaxoSmithKline’s Vaccines Business Reported Growth in 4Q16 Feb 15 2017
4Q16 Performance of GlaxoSmithKline’s Business Segments Feb 14 2017
Novartis’s Innovative Medicines Segment in 4Q16 Feb 01 2017
PotashCorp in 4Q16: Nitrogen Prices Added Salt to the Wound Jan 30 2017
Novartis’s 4Q16 Estimates: Innovative Medicines Segment Jan 23 2017
How Did Novartis’s Generics Business Perform in 3Q16? Jan 17 2017
How GlaxoSmithKline’s Pharmaceuticals Segment Has Performed Dec 30 2016
4 High Dividend ETFs Under $20 Dec 13 2016
PowerShares Announces Listing Transfer for 27 ETFs Nov 23 2016
How Sandoz Performed for Novartis in 3Q16 Nov 17 2016
How Tresiba Helps Novo Achieve Its Growth Targets Nov 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK